Kristin Baltrusaitis, Bonus Makanani, Camlin Tierney, Mary Glenn Fowler, Dhayendre Moodley, Gerhard Theron, Lynette H Nyakudya, Musunga Tomu, Lee Fairlie, Kathleen George, Barbara Heckman, Kevin Knowles, Renee Browning, George K Siberry, Taha E Taha, Lynda Stranix-Chibanda
BACKGROUND: Tenofovir disoproxil fumarate (TDF) in combination with other antiretroviral (ARV) drugs has been in clinical use for HIV treatment since its approval in 2001. Although the effectiveness of TDF in preventing perinatal HIV infection is well established, information about renal safety during pregnancy is still limited. TRIAL DESIGN: The IMPAACT PROMISE study was an open-label, strategy trial that randomized pregnant women to one of three arms: TDF based antiretroviral therapy (ART), zidovudine (ZDV) based ART, and ZDV alone (standard of care at start of enrollment)...
July 20, 2022: BMC Infectious Diseases